| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_435f32b3c97f1536736ed161298cd740 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D285-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5042
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5047
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5026
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D285-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-549
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-549
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate |
2020-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_061992efd2d5f948f007f7bfd9347d86 |
| publicationDate |
2020-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2020073566-A |
| titleOfInvention |
Method for treating a subject having Prader-Willi syndrome or Smith-Magenis syndrome |
| abstract |
A method of treating a subject having Prader-Willi syndrome (PWS) or Smith-Magenis syndrome (SMS). A method comprising administering to a subject a pharmaceutical formulation comprising an effective amount of a K ATP channel opener for at least 10 weeks. The KATP channel opener is diazoxide or a pharmaceutically acceptable salt thereof. The pharmaceutically acceptable salt is diazoxide choline. Diazoxide or a pharmaceutically acceptable salt thereof is administered orally. The pharmaceutical formulation comprises at least one excipient that affects the release rate of diazoxide or a pharmaceutically acceptable salt thereof. The pharmaceutical formulation comprises at least one excipient that delays the release of diazoxide or a pharmaceutically acceptable salt thereof. [Selection diagram] Figure 1 |
| priorityDate |
2014-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |